Standigm Company

Standigm is a workflow AI-driven drug discovery company headquartered in Seoul, South Korea. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing.
Technology: Data-driven Technologies
Industry: Preclinical Development
Headquarters: Seoul, Seoul-t'ukpyolsi, South Korea
Founded Date: 04.05.2015
Employees Number: 51-100
Funding Status: Late Stage Venture
Total Funding: $80 M
Estimated Revenue: $1M to $10M
Last Funding Date: 43553
Last Funding Type: Series B

Visit Website
business@standigm.com
https://www.twitter.com/ebdgroup
Register and Claim Ownership